Theranos has come out swinging against The Wall Street Journal following a series of articles questioning the science behind the diagnostic company’s blood testing tech, which involves taking a miniscule amount of blood from a fingerprick and evaluating it for different conditions.
It’s a unique position for a company that’s been valued at $9 billion and has enjoyed so much undiluted hype prior to and after receiving its first FDA clearance for a diagnostic test over the summer.
This week on MedHeads, life science reporter Meghana Keshavan and medical device reporter Nicole Oran will be joined by moderator Chris Seper to talk about the fallout, and whether Elizabeth Holmes has effectively deflected the criticism.
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
Tune in to MedHeads at 4 pm Eastern Friday when the reporters discuss whether Theranos has been dealt a debilitating setback or just a flesh wound.
Watch the gab session via the YouTube embed below or on our Google Hangout on Air page. Join us as the MedCity News team talks about the week that was in healthcare innovation.
Photo: BigStockPhotos
